Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-232
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-232 is an investigational, orally administered small molecule drug candidate being developed by Addpharma, a South Korean pharmaceutical research and development company specializing in incrementally modified drugs (IMDs). The candidate is currently in Phase 1 clinical development for the treatment of hypertension. As an IMD, AD-232 is designed to improve patient convenience, compliance, or therapeutic efficacy compared to existing therapies, potentially through a novel fixed-dose combination, controlled-release formulation, or enhanced bioavailability. However, the specific active pharmaceutical ingredients and molecular targets of AD-232 remain proprietary and have not been publicly disclosed.
Beyond the preview
Go deeper on AD-232.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-232.